Loading...
•
Sep 30, 2022
Cardiff Oncology Q3 2022 Earnings Report
Reported third quarter 2022 results and provided business updates.
Key Takeaways
Cardiff Oncology announced Phase 1b/2 data demonstrating onvansertib's ability to generate durable responses in KRAS-mutated mCRC patients. The company plans to activate ONSEMBLE, a randomized Phase 2 trial in Q4 2022. Cardiff Oncology had approximately $114 million in cash, cash equivalents, and short-term investments as of September 30, 2022, providing projected runway into 2025.
Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC) show durable responses to treatment.
Data support initiation of ONSEMBLE, a randomized Phase 2 trial in KRAS/NRAS-mutated mCRC.
ONSEMBLE trial on track for activation in Q4 2022.
Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, 2022, provide projected runway into 2025.
Forward Guidance
The Company believes its current cash resources are sufficient to fund its operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...